A case-control study suggests that the CCR6 locus is not involved in the susceptibility to giant cell arteritis
A. Serrano, F.D. Carmona, S. Castañeda, J.A. Miranda-Filloy, I.C. Morado, C. Gomez-Vaquero, R. Solans, B. Sopeña, R. Blanco, A. Unzurrunzaga, N. Ortego-Centeno, B. Marí-Alfonso, A. Hidalgo-Conde, J. Hernández- rodríguez, M.C. Cid, J. Martín, M.A. Gonzalez-Gay
2013 Vol.31, N°1 ,Suppl.75
PI 0005, PF 0008
Free to view
(click on article PDF icon to read the article)
PMID: 23306142 [PubMed]
Accepted : 13/06/2012
In Press: 07/01/2013
Polymorphisms of the CC chemokine receptor 6 (CCR6) gene have been recently reported to be associated with a number of autoimmune diseases. We aimed to investigate the possible influence of CCR6 rs3093024 gene variant in the susceptibility to and clinical expression of GCA.
The CCR6 polymorphism rs3093024 was genotyped in a total of 463 Spanish patients diagnosed with biopsy-proven GCA and 920 healthy controls using a TaqMan® allelic discrimination assay. PLINK software was used for the statistical analyses.
No significant association between this CCR6 variant and GCA was observed (p=0.42, OR=0.94, CI95% 0.79–1.10). Similarly, when patients were stratified according to the specific clinical features of GCA such as polymyalgia rheumatica, visual ischaemic manifestations or irreversible occlusive disease, no statistical significant difference was detected either between the case subgroups and the control set or between GCA patients with and without the specific features of the disease.
Our results suggest that the CCR6 rs3093024 polymorphism may not play a relevant role in the GCA pathophysiology.